Trials / Sponsors / Li Zhang, MD
Li Zhang, MD
Academic / Other · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Unknown | Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung | Phase 2 | 2021-12-08 |
| Unknown | Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance The Diagnosis Was ALK Positive NSCLC, Second Generation ALK-TKI is Resistant, Efficacy of Ensatinib in This Subset of Patients | Phase 2 | 2021-12-01 |
| Unknown | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese Lung Cancer, Small Cell Lung Cancer, Durvalumab | Phase 2 | 2021-08-21 |
| Active Not Recruiting | Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations Non-small Cell Carcinoma, EGFR Gene Mutation | Phase 3 | 2021-03-29 |
| Unknown | JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. Non-small Cell Lung Cancer | Phase 2 | 2020-08-31 |